Corvus Pharmaceuticals(CRVS)

Search documents
Corvus Pharmaceuticals(CRVS) - 2025 Q1 - Earnings Call Presentation
2025-07-04 07:38
Soquelitinib Atopic Dermatitis Phase 1 Data - A Phase 1 clinical trial of Soquelitinib in Atopic Dermatitis (AD) demonstrated activity through a novel mechanism of action[7] - The study included 64 participants with moderate to severe AD, randomized into different Soquelitinib dosage cohorts (100 mg BID, 200 mg QD, 200 mg BID, 400 mg QD) and placebo groups[9] - In Cohorts 1 and 2, the Soquelitinib group (N=24) showed a 54.6% mean reduction in EASI score at 4 weeks, compared to a 30.6% reduction in the placebo group (N=8)[15] - In Cohort 3, the Soquelitinib group (N=8) achieved a 71.1% mean reduction in EASI score at 4 weeks, while the placebo group (N=4) had a 42.1% reduction[15] - At day 28, 63% of patients in Soquelitinib Cohort 3 achieved EASI 75, and 25% achieved IGA 0 or 1, compared to 0% in the placebo group[21] - Across Cohorts 1, 2, and 3, 33.3% of Soquelitinib-treated subjects (N=36) experienced Adverse Events (AEs), compared to 25% in the placebo group (N=12)[22] Business Update and Protocol Amendment - A protocol amendment replaces Cohort 4 with an extension cohort to optimize Phase 2 plans, increasing the treatment duration to 8 weeks for 24 patients randomized 1:1 to Soquelitinib 200 mg BID or placebo[24, 25, 26] - The extension cohort will evaluate a longer 56-day treatment duration[27]
Corvus Pharmaceuticals (CRVS) Earnings Call Presentation
2025-07-04 07:37
Soquelitinib作用机制和潜力 - Soquelitinib 是一种 First-in-Class 的免疫调节剂,在癌症和免疫疾病领域具有广泛的机会[4] - Soquelitinib 通过阻断 ITK 信号通路,能够调节 Th1/Th2/Th17 细胞的平衡,从而影响多种炎症细胞因子的产生[11, 29] - ITK 抑制剂具有广阔的治疗潜力,包括肿瘤免疫治疗、免疫疾病、肺部炎症、胃肠道疾病、纤维化疾病和皮肤病等[7] - Corvus 团队的领导成员曾参与 rituximab 和 ibrutinib 的开发[5] Soquelitinib 在 Atopic Dermatitis (AD) 临床试验中的结果 - 在 AD 的 Phase 1 临床试验中,Soquelitinib 在 Cohorts 1 和 2 中显示出 54.6% 的 EASI 平均降低[42] - Cohort 3 的 EASI 平均降低为 64.8%[42] - Cohort 3 中,50% 的患者在第 28 天实现了 PP-NRS 评分至少降低 4 分,表明瘙痒症状得到显著改善[53] - 在接受 Soquelitinib 治疗的患者中,75% 在 EASI 50 中有所改善,83% 在 EASI 50 中有所改善[42] - 29% 的患者在 EASI 75 中有所改善,50% 的患者在 EASI 75 中有所改善[42] - 4% 的患者在 EASI 90 中有所改善,8% 的患者在 EASI 90 中有所改善[42] - 21% 的患者 IGA 0 或 1 中有所改善,25% 的患者 IGA 0 或 1 中有所改善[42] Soquelitinib 的安全性 - 在 Cohorts 1、2 和 3 中,Soquelitinib 表现出良好的安全性和耐受性,未发生严重不良事件[49] - 38.9% 的 Soquelitinib 治疗患者出现不良反应,而安慰剂组为 25%[49] AD 市场机会 - G7 国家有大约 30 million 的 AD 患者,其中约 3 million 为中重度患者,但只有 10% 接受了先进疗法治疗[34] - AD 市场预计到 2030 年将达到 280 亿美元[34]
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Globenewswire· 2025-06-25 12:00
Core Viewpoint - Corvus Pharmaceuticals has announced the approval of an IND application for a Phase 1b/2 clinical trial of soquelitinib in China, targeting patients with moderate-to-severe atopic dermatitis, which is expected to begin patient enrollment in Q3 2025 [1][3]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy approach for various cancers and immune diseases [6][7]. - Angel Pharmaceuticals, co-founded by Corvus, is responsible for developing, manufacturing, and commercializing soquelitinib in greater China, with Corvus holding approximately 49.7% ownership [2][5]. Clinical Trial Details - The Phase 1b/2 trial will study a 12-week treatment period with a 400 mg once-daily dose of soquelitinib, building on previous clinical data [3][6]. - The trial will be randomized, double-blinded, and placebo-controlled, enrolling patients with moderate-to-severe atopic dermatitis [3][6]. - The Phase 1b trial will include two cohorts, each with 24 patients, testing different dosing regimens [6]. Market Context - Atopic dermatitis is a growing concern globally, with increasing use of biologics and systemic therapies, particularly in China [3].
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
Globenewswire· 2025-06-11 11:00
SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11- 14, 2025 in Barcelona. The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist a ...
Corvus Pharmaceuticals (CRVS) 2025 Conference Transcript
2025-06-05 14:20
Corvus Pharmaceuticals (CRVS) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Alright. Welcome, everyone, to Jefferies twenty twenty five, global health care conference. My name is Roger Song, one of the senior analysts covering semi cap biotech in The US. It's my pleasure to introduce our next printing company covers. We have the CEO, Rich Miller. Speaker1 Thank you Roger and good morning everyone. I want to thank Jeffries for the invitation to the healthcare conference and thank you all for attending. ...
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewswire News Room· 2025-06-04 11:00
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8- week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clin ...
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Globenewswire· 2025-05-28 20:01
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days fol ...
Why Is Corvus Pharmaceuticals Stock Soaring On Friday?
Benzinga· 2025-05-09 15:57
Core Insights - Corvus Pharmaceuticals released new interim data from a Phase 1 clinical trial for soquelitinib, showing a favorable safety and efficacy profile in patients with moderate to severe atopic dermatitis [1][6] Efficacy and Safety Data - All three cohorts demonstrated significant responses in EASI 75 and IGA 0 or 1 compared to placebo [2] - The percent reduction in mean EASI scores at 28 days was 54.6% for cohorts 1 and 2 combined receiving soquelitinib versus 30.6% for placebo, while cohort 3 showed a 71.1% reduction compared to 42.1% for placebo [3] - Active drug separation from placebo began at day 15 for cohorts 1 and 2, and at day 8 for cohort 3, with significant superiority at day 28 (p=0.03) [4] Tolerability and Adverse Events - Soquelitinib was well tolerated with no dose-limiting toxicities or clinically significant laboratory abnormalities observed [4] - Grade 1/2 adverse events occurred in 33.3% of soquelitinib patients and 25% of placebo patients, with only one treatment-related adverse event reported [5] Mechanism of Action and Future Plans - Relationships between reductions in certain cytokines and improvement in EASI scores were observed, along with an increase in circulating T regulatory cells [5] - The company plans to continue with key initiatives for soquelitinib, including data from a new extension cohort and a Phase 2 clinical trial by year-end [7] Financial Position - As of March 31, 2025, Corvus had cash and equivalents of $44.2 million, expected to fund operations into Q4 2026 [8] - Following the news, CRVS stock increased by 28.40% to $4.30 [8]
Corvus Pharmaceuticals(CRVS) - 2025 Q1 - Earnings Call Transcript
2025-05-08 21:32
Corvus Pharmaceuticals (CRVS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Zack Kubow - Managing DirectorLeiv Lea - Chief Financial OfficerRichard Miller - Co-Founder, President, CEO & Chairman of the BoardGraig Suvannavejh - Managing DirectorLi Watsek - DirectorSean Lee - VP - Equity Research Conference Call Participants Aydin Huseynov - Equity Research AnalystJeff Jones - Managing Director and Senior AnalystRoger Song - Senior Equity Research Analyst Operator Good afternoon, everyon ...
Corvus Pharmaceuticals(CRVS) - 2025 Q1 - Earnings Call Transcript
2025-05-08 21:30
Corvus Pharmaceuticals (CRVS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, everyone. Thank you for standing by, and welcome to the Carvus Pharmaceuticals first quarter twenty twenty five business update and financial results conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo of Real Chemistry. Please go ah ...